Carbon-Ion Radiotherapy Plus Camrelizumab With or Without Apatinib for Locally Recurrent Nasopharyngeal Carcinoma

2019-11-03 15:10:53 | BioPortfolio


The purpose of this trial is to examine the role of camrezlizumab with or without apatinib in addition to carbon-ion radiotherapy (CIRT) for patients with locally recurrent nasopharyngeal carcinoma. According to the plan, a total of 114 will be recruited and randomized into 1 of the following 3 groups in a 1:1:1 ratio: 1) CIRT alone group (patients will receive only carbon-ion radiotherapy); 2) CIRT plus camrelizumab group (patients will also receive camrelizumab in addition to CIRT); 3) CIRT plus camrelizumab and apatinib group (patients will receive camrelizumab and apatinib in addition to CIRT).

Study Design


Nasopharyngeal Carcinoma


Carbon-ion radiotherapy, Camrelizumab, Apatinib


Not yet recruiting


Shanghai Proton and Heavy Ion Center

Results (where available)

View Results


Published on BioPortfolio: 2019-11-03T15:10:53-0500

Clinical Trials [1710 Associated Clinical Trials listed on BioPortfolio]

Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma

The main purpose of this study is to see how well the experimental drug camrelizumab(SHR-1210) works in people with oligometastatic NPC who have already had locally radiotherapy for their ...

Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant

To assess the primary effects and safety of camrelizumab (SHR-1210) plus apatinib for downstaging/bridging of HCC before liver transplantation.

Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma

This study is a randomized, placebo-controlled, double-blind, multicenter phase III clinical study. Target population is patients with recurrent/metastatic nasopharyngeal carcinoma who had...

Camrelizumab Combined With Apatinib for Recurrent Resistant GTN: a Phase 2 Single-arm Prospective Study

This study is intend to improve the progression free survival in treatment of camrelizumab combined with apatinib in platinum-resistant recurrent patients.

Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

To evaluate the efficacy and safety of apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who failed prior platinum based chemotherapy

PubMed Articles [8003 Associated PubMed Articles listed on BioPortfolio]

The effectiveness of intensity-modulated radiation therapy versus 2D-RT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis.

At present, the management of nasopharyngeal carcinoma (NPC) is mainly based on radiotherapy, but there are many radiation delivery techniques such as intensity-modulated radiotherapy (IMRT) and 2-dim...

Hopkins criteria for residual disease assessment after definitive radiotherapy in nasopharyngeal carcinoma.

Assessment of viable tumor residue after definitive radiotherapy is essential in patients with nasopharyngeal carcinoma (NPC). This study aimed to investigate the use of Hopkins criteria on positron e...

Complete response of early stage hepatocellular carcinoma in a patient treated with combination therapy of camrelizumab (SHR-1210) and apatinib.

Comparison of Dose Distributions When Using Carbon Ion Radiotherapy Versus Intensity-modulated Radiotherapy for Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Retrospective Analysis.

This study compared the dose distributions of carbon ion radiotherapy (C-ion RT) and intensity-modulated radiotherapy (IMRT) in patients with locally advanced hepatocellular carcinoma (LAHCC).

The efficacy of chemotherapy in survival of stage II nasopharyngeal carcinoma.

Chemotherapy use remains controversial for stage II nasopharyngeal carcinoma (NPC). This retrospective study was conducted to identify whether chemoradiotherapy was associated with better survival com...

Medical and Biotech [MESH] Definitions

The use of a heavy ion particle beam for radiotherapy, such as the HEAVY IONS of CARBON.

A variant of well-differentiated epidermoid carcinoma that is most common in the oral cavity, but also occurs in the larynx, nasal cavity, esophagus, penis, anorectal region, vulva, vagina, uterine cervix, and skin, especially on the sole of the foot. Most intraoral cases occur in elderly male abusers of smokeless tobacco. The treatment is surgical resection. Radiotherapy is not indicated, as up to 30% treated with radiation become highly aggressive within six months. (Segen, Dictionary of Modern Medicine, 1992)

Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.

The total amount of radiation absorbed by tissues as a result of radiotherapy.

A condition in which abnormal cells have not spread outside the duct, lobule, or nipple to other tissues of the breast. There are 3 types of breast carcinoma in situ: DUCTAL CARCINOMA IN SITU; LOBULAR CARCINOMA IN SITU; and PAGET DISEASE OF THE NIPPLE

More From BioPortfolio on "Carbon-Ion Radiotherapy Plus Camrelizumab With or Without Apatinib for Locally Recurrent Nasopharyngeal Carcinoma"

Quick Search

Searches Linking to this Trial